Quince Therapeutics (QNCX) Expected to Post Earnings on Tuesday

Quince Therapeutics (NASDAQ:QNCX) will likely be announcing its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of ($28.02) per share for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Quince Therapeutics (NASDAQ:QNCX) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($26.00) by $25.41. On average, analysts expect Quince Therapeutics to post $-3 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Quince Therapeutics Stock Up 1.2%

QNCX stock traded up $0.29 during midday trading on Tuesday, hitting $25.26. The company’s stock had a trading volume of 7,922 shares, compared to its average volume of 247,951. Quince Therapeutics has a 12 month low of $15.10 and a 12 month high of $909.98. The company has a 50 day moving average of $19.45 and a two-hundred day moving average of $72.58. The firm has a market capitalization of $24.75 million, a price-to-earnings ratio of -0.12 and a beta of 1.36.

Institutional Investors Weigh In On Quince Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QNCX. Superstring Capital Management LP bought a new stake in shares of Quince Therapeutics in the 4th quarter valued at approximately $2,877,000. Quadrature Capital Ltd purchased a new stake in Quince Therapeutics during the 4th quarter valued at $268,000. Almitas Capital LLC lifted its position in Quince Therapeutics by 88.0% in the fourth quarter. Almitas Capital LLC now owns 930,134 shares of the company’s stock worth $3,116,000 after buying an additional 435,356 shares during the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in Quince Therapeutics during the fourth quarter worth $7,538,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in Quince Therapeutics during the fourth quarter worth $308,000. 30.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

QNCX has been the subject of a number of research reports. Lifesci Capital upgraded shares of Quince Therapeutics to a “strong-buy” rating in a research report on Monday, June 29th. Oppenheimer began coverage on shares of Quince Therapeutics in a report on Wednesday, July 29th. They issued an “outperform” rating and a $82.00 price target on the stock. Cantor Fitzgerald assumed coverage on shares of Quince Therapeutics in a report on Tuesday, June 23rd. They set an “overweight” rating and a $80.00 price objective for the company. Leerink Partners initiated coverage on shares of Quince Therapeutics in a report on Wednesday, June 24th. They set an “outperform” rating and a $80.00 price objective for the company. Finally, Wall Street Zen upgraded Quince Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 17th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $568.40.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.